SCHEMBL30357709

SCHEMBL30357709

Cc1nc(C#N)ccc1-n1cnc(-c2nc(NC3CCN(C(=O)OC(C)(C)C)CC3)ncc2C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 6/20 0.44
▸ CCNE1 P24864 5/20 0.42
▸ CDK2 P24941 5/20 0.42
▸ CDK7 P50613 4/20 0.42
▸ CCNH P51946 4/20 0.42
▸ MNAT1 P51948 4/20 0.42
▸ CDK1 P06493 3/20 0.42
▸ CDK4 P11802 3/20 0.42
▸ CCNB1 P14635 3/20 0.42
▸ CCND1 P24385 3/20 0.42
▸ CCND3 P30281 3/20 0.42
▸ CDK6 Q00534 3/20 0.42
▸ CCNT1 O60563 2/20 0.42
▸ CDK9 P50750 2/20 0.42
▸ SYK P43405 1/20 0.41
▸ IDH1 O75874 1/20 0.40
▸ IDH2 P48735 1/20 0.40
▸ NSD2 O96028 2/20 0.39
▸ EHMT2 Q96KQ7 1/20 0.39
▸ CCNK O75909 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22977174 1.00 GPR119 (0.44) GPR119CCNE1CDK2CDK7CCNH
SCHEMBL22983942 0.91 CCNE1 (0.44) CCNE1CDK2CDK7CCNHMNAT1
SCHEMBL22977024 0.85 CCNE1 (0.59) CCNE1CDK2CDK7CCNHMNAT1
SCHEMBL22977117 0.84 CCNE1 (0.51) CCNE1CDK2CDK7CCNHMNAT1
SCHEMBL22977403 0.84 CDK7 (0.51) CCNE1CDK2CDK7CCNHMNAT1
SCHEMBL30449196 0.84 CDK7 (0.51) CCNE1CDK2CDK7CCNHMNAT1
SCHEMBL30357712 0.82 GPR119 (0.49) GPR119CCNE1CDK2CDK7CCNH
SCHEMBL22977446 0.82 GPR119 (0.49) GPR119CCNE1CDK2CDK7CCNH
SCHEMBL30810461 0.81 CCNE1 (0.50) GPR119CCNE1CDK2CDK7CCNH
SCHEMBL22997743 0.80 CDK4 (0.40) GPR119CCNE1CDK2CDK7CCNH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2025-07-31 — — US disclosed
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2025-05-27 — — US disclosed
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors CDK2, CDK4, CDK2AP2 GPR119 3073/4885CCNE1 43/4885CDK2 1/4885
US-20230024173-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 GPR119 3073/4885CCNE1 43/4885CDK2 1/4885
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 GPR119 3073/4885CCNE1 43/4885CDK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback